Daiichi To Market New Hib Vaccine For Children In December
This article was originally published in PharmAsia News
Daiichi Sankyo plans to begin marketing a new hemophilus influenza type B vaccine for children in Japan beginning Dec. 19. The ActHIB drug was developed by Sanofi Pasteur of France. Japan accounts for 25 of the estimated 400,000 deaths globally from the disease that usually is caused by meningitis and pneumonia. The disease usually strikes children between the ages of four and 18 months of age, and about 500 are affected by it in Japan each year. (Click here for more
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
Increasing number of product development meetings suggests that many complex generics remain in the development stages.